Limit search to items available for checkout
6 results found. Sorted by relevance | date | title .
E-BOOK
Title Handbook of therapeutic biomarkers in cancer / edited by Sherry X. Yang, Janet E. Dancey.
Imprint Singapore : Jenny Stanford Publishing, [2021]

Copies/Volumes

LOCATION CALL # STATUS
 Internet  Electronic Book    AVAILABLE
Edition Second edition.
Description 1 online resource (xx, 677 pages) : illustrations
Bibliog. Includes bibliographical references and index.
Note 4.2.4 HER-2 Amplification as a Predictive Biomarker for Response to Chemotherapy in Breast Cancer.
Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK). WlAbNL.
Available only to authorized UTEP users.
Bio/Hist Note Sherry X. Yang is a physician and program director of the Cancer Diagnosis Program, National Cancer Institute (NCI), USA. She serves as a member of the Biomarker Review Committee of the NCI-sponsored clinical trials and the NCI ComboMATCH Molecular Biomarker and Specimen Management Committee. Dr. Yang was chief of National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, NCI, from 2006 to 2019. She has implemented the translational oncology research initiative for predictive and prognostic biomarkers in cancer treatment toward precision medicine. Her team recently discovered the performance of prognostic factors, including breast cancer subtypes, that was driven by treatment modality and weighted by the type of clinical endpoints with reference to untreated patients. She is a recipient of several biomarker-related awards and innovations. Janet E. Dancey is director of the Canadian Cancer Trials Group and professor in the Department of Oncology, Queen's University, Canada. Previously, she was associate chief of the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the NCI, USA. In her current position, Dr. Dancey is responsible for the development and oversight of CCTG clinical trials activities. Her clinical focus is on melanoma and gastrointestinal malignancies.
Note Description based on online resource; title from digital title page (viewed on February 26, 2021).
Subject Tumor markers -- Handbooks, manuals, etc.
Cancer -- Diagnosis -- Handbooks, manuals, etc.
Cancer -- Treatment -- Handbooks, manuals, etc.
Genre Handbooks and manuals.
Contents Cover -- Half Title -- Title Page -- Copyright Page -- Contents -- Preface -- 1. Overview of Therapeutic Biomarkers in Cancer -- 1.1 Introduction -- 1.2 Classification of Therapeutic Biomarkers -- 1.3 Chemotherapy Agents and Therapeutic Biomarkers -- 1.4 Targeted Cancer Therapeutics and Biomarkers -- 1.4.1 Targeted Therapeutics -- 1.4.2 Biomarker Validation and Clinical Decision -- 1.4.3 Therapeutic Biomarkers for Targeted Therapy -- 1.4.3.1 Direct drug targets as therapeutic biomarkers -- 1.4.3.2 Indirect drug targets as therapeutic biomarkers.
1.4.3.3 Anti-angiogenesis therapy and biomarkers -- 1.5 Targeted Therapeutics in Combination with Chemotherapy or Immunotherapy and Therapeutic Biomarkers -- 1.6 Multi-Gene Expression or Signatures for Prognosis and Treatment -- 1.7 Diagnostic Techniques for Therapeutic Biomarkers -- 1.8 Conclusions and Perspectives -- 2. Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer -- 2.1 Introduction -- 2.2 Analytical Performance of a Biomarker-Based Test -- 2.3 Prognostic versus Predictive Biomarkers -- 2.4 Biomarker Evaluations in Phase I Trials.
2.5 Biomarker Evaluations in Phase II Trials -- 2.5.1 Designs Involving Single Biomarkers -- 2.5.2 Designs Involving Multiple Biomarkers -- 2.6 Biomarker Evaluations in Phase III Trials -- 2.6.1 Biomarker-Stratified Designs -- 2.6.2 Enrichment Designs -- 2.6.3 Biomarker-Strategy Designs -- 2.6.4 Designs in Which the Biomarker Has Not Been Completely Specified -- 2.7 Summary -- 3. Role of Biomarkers in Clinical Development of Cancer Therapies -- 3.1 Introduction -- 3.2 A Few Definitions and General Concepts -- 3.3 Role of Biomarkers in the Different Stages of Drug Development.
3.3.1 Use of PD Markers in Phase I and Early-Stage Proof of Principle Studies -- 3.3.1.1 Role of PD markers in verifying target engagement -- 3.3.1.2 Role of PD markers in decisions on the recommended phase II dose: value and limitations -- 3.3.1.3 Use of distal PD markers to measure the biological and molecular consequences of target inhibition -- 3.3.2 Incorporation and Exploration of Patient Selection Markers in Early Clinical Trials -- 3.3.2.1 Trial design for patient selection markers -- 3.3.2.2 Scientific and technical challenges of predictive markers.
3.4 Conclusions and Future Directions -- 4. HER-2 as a Prognostic and Predictive Biomarker in Cancer -- 4.1 Introduction -- 4.2 Biology of HER-2 -- 4.2.1 HER-2 Amplification and Overexpression: Methods of HER-2 Measurement -- 4.2.2 HER-2 Amplification as a Prognostic Biomarker in Breast Cancer -- 4.2.3 HER-2 Amplification as a Predictive Biomarker for Response to HER-2 Targeted Agents in Breast Cancer -- 4.2.3.1 Trastuzumab -- 4.2.3.2 Lapatinib -- 4.2.3.3 Pertuzumab -- 4.2.3.4 Neratinib -- 4.2.3.5 Tucatinib.
Summary This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine--a precisely tailored cancer treatment strategy for cancer patient care.
Other Author Yang, Sherry X., editor.
Dancey, Janet E., editor.
Other Title Print version: Yang, Sherry X. Handbook of Therapeutic Biomarkers in Cancer Milton : Jenny Stanford Publishing,c2021 9789814877008.